Alendronate reduces the daily consumption of insulin (DCI) in patients with senile type I diabetes and osteoporosis

Maugeri, D.; Panebianco, P.; Rosso, D.; Calanna, A.; Speciale, Salvatore; Sant’Angelo, Antonino; Rizza, I.; Motta, Massimo; Lentini, A; Malaguarnera, Mariano

doi:10.1016/s0167-4943(01)00202-3

Cited by 26 publications

(13 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oral etidronate has been shown to decrease carotid arterial intima—media thickness in type 2 diabetes without changing cardiovascular parameters, suggesting a direct effect of bisphosphonates on the vascular wall 44 . In elderly patients with diabetes, the use of alendronate for the treatment of osteoporosis was associated with a 36% reduction in daily insulin dosage 45 . This suggests improvement in insulin sensitivity associated with bisphosphonate use.…”

Section: Therapeutic Agentsmentioning

confidence: 99%

Bone Metabolism and the Cardiometabolic Syndrome: Pathophysiologic Insights

McFarlane

2006

J Cardiometabolic Synd

View full text Add to dashboard Cite

Accumulating evidence indicates that the several components of the cardiometabolic syndrome such as hypertension, increased triglycerides, and reduced high-density lipoprotein cholesterol are also risk factors for low bone mineral density. Furthermore, some of the underlying risk factors for atherosclerosis in the cardiometabolic syndrome, such as inflammation, also play a major role in the pathogenesis of osteoporosis, the most common metabolic bone disease. In this article for the premiere issue of the Journal of the CardioMetabolic Syndrome, the author presents the current evidence of the interaction of bone metabolism and the cardiometabolic syndrome, highlighting the major research in this area and discussing the potential of therapeutic agents that will be useful in the treatment of osteoporosis as well as atherosclerosis.

show abstract

Section: Therapeutic Agentsmentioning

confidence: 99%

Bone Metabolism and the Cardiometabolic Syndrome: Pathophysiologic Insights

McFarlane

2006

J Cardiometabolic Synd

View full text Add to dashboard Cite

show abstract

“…A study of elderly patients with T1DM found that those who were taking the bisphosphonate alendronate had a reduced insulin requirement compared with those receiving only calcium and vitamin D. 112 In a large population based study in Denmark, a reduced risk of T2DM was found in individuals receiving alendronate, etidronate and raloxifine. 113 The conclusions are indirect, as no markers of bone turnover were measured in these studies.…”

Section: The Influence Of Bone Active Agentsmentioning

confidence: 99%

The role of osteocalcin in human glucose metabolism: marker or mediator?

et al. 2012

View full text Add to dashboard Cite

Increasing evidence supports an association between the skeleton and energy metabolism. These interactions are mediated by a variety of hormones, cytokines and nutrients. Here, the evidence for a role of osteocalcin in the regulation of glucose metabolism in humans is reviewed. Osteocalcin is a bone matrix protein that regulates hydroxyapatite size and shape through its vitamin-K-dependent γ-carboxylated form. In circulation, the concentration of osteocalcin is a measure of bone formation. The undercarboxylated form of osteocalcin is reported to be active in glucose metabolism in mice. Total serum osteocalcin concentrations in humans are inversely associated with measures of glucose metabolism; however, human data are inconclusive with regard to the role of uncarboxylated osteocalcin in glucose metabolism because most studies do not account for the influence of vitamin K on the proportion of undercarboxylated osteocalcin or differentiate between the total and uncarboxylated forms of osteocalcin. Furthermore, most human studies do not concomitantly measure other bone turnover markers to isolate the role of osteocalcin as a measure of bone formation from its effect on glucose metabolism. Carefully designed studies are required to define the role of osteocalcin and its carboxylated or undercarboxylated forms in the regulation of glucose metabolism in humans.

show abstract

“…27 Salmon calcitonin is a synthetic polypeptide that duplicates the molecular structure of calcitonin found in the salmon fish. Salmon calcitonin is more 34 Larger confirmatory trials are needed.…”

mentioning

confidence: 99%

“…In fact, a recent small trial sug- [32][33][34][35][36][37][38]1997 16 Gregorio F, Cristallini S, Santeusanio F, Filipponi P, Fumelli P: Osteopenia associated with…”

mentioning

confidence: 99%